The pharmaceutical sector is still a hub for new patent developments. The development of novel treatment paradigms, the severity of unfulfilled requirements, and the increasing significance of technology like pharmacogenomics, digital therapies, and artificial intelligence are what propel activity. According to GlobalData’s study on Innovation in pharma: drug delivery nanoparticles, there have been over 136,000 patents filed and issued in the pharmaceutical business in only the previous three years.
But not all inventions are created equal, and they don’t always go up. Rather, an S-shaped curve represents their progression, which matches their normal lifetime of early emergence, rapid acceptance, and eventual stabilization and maturity.
Understanding an innovation’s present acceptance level, expected future trajectory, and potential effect all depend on where it is in its journey. It is particularly true for innovations that are in the emerging or accelerating phases.
The pharmaceutical sector will be shaped by almost 80 developments.
There are more than 80 innovation areas that will influence the pharmaceutical industry’s future, according to GlobalData’s Technology Foresights, which uses innovation intensity models based on more than 730,000 patents to construct the S-curve for the sector.
Tyrosine kinase inhibitors, mutant DNA polymerases, and modified multispecific antibodies are disruptive technologies in the early phases of application that should be constantly monitored within the emerging innovation stage. Adoption of the accelerated innovation fields, such as peptide pharmacophores, antibody-drug conjugates, and neuroprotective medicines, has been gradually rising. Targeted therapeutics for amyloid precursors and modified vector HIV-1 vaccines, which are already well-established in the market, are examples of mature innovation domains.
Drug delivery using nanoparticles is a significant advancement in the pharmaceutical
A nanoparticle is a tiny particle with a size range of one to one hundred nanometers. Controlled release treatment and targeted tissue distribution are two new uses for nanoparticles in medication administration. Patients are more likely to comply with less frequent doses and suffer less medication toxicity when pharmaceuticals are delivered in a focused and sustained manner. The most prevalent kinds of nanoparticles include metal, liposome, nanocrystal, and polymeric nanoparticles. One of the main benefits of this is the delivery of insoluble medications into the bloodstream via stable colloidal systems and regulated drug release.
Additionally, GlobalData’s study identifies the leading businesses in each field of innovation and evaluates the possible effect and reach of their patenting activities across various applications and geographical areas. The research and use of nanoparticles for medication delivery is being carried out by 130 firms, including technology suppliers, well-known pharmaceutical corporations, and emerging start-ups, according to GlobalData.
Application diversity quantifies how many applications are found for every patent. It divides businesses into two categories: “diversified” and “niche” innovators.
The term “geographic reach” describes how many nations each patent is registered in. It illustrates the range of planned geographic use, from “global” to “local.”
The company that files the most patents for medication delivery nanoparticles is Bristol-Myers Squibb. With a $125.28 billion market valuation, BMS is mainly focused on therapeutic initiatives related to cancer, hematology, cardiovascular disease, immunology, and fibrosis. Abraxane, a PX albumin-bound nanoparticle formulation with 130 nm particles, was authorized by the FDA in 2005 by Bristol-Myers Squibb to treat metastatic breast cancer. The two major patent filers in the field of medication delivery using nanoparticles are Ipsen and Insmed.
Well Shield is the leading business in terms of application variety, followed by Intezyne and Crystalplex.
In terms of geographic reach, Insmed is in the lead. Second and third place go to South Korean pharmaceutical business Yuhan and Laboratory Skin Care, respectively.
View the most recent Pharmaceutical thematic study report from GlobalData to learn more about the major topics and emerging technologies that are upending the pharmaceutical sector.
